Tris Pharma appoints Mahdi Fawzi CSO
This article was originally published in Scrip
Executive Summary
Emerging specialty pharma company Tris Pharma, which focuses on technologies based products, has appointed Dr Mahdi Fawzi chief scientific officer and executive vice-president of R&D including regulatory affairs. Most recently Dr Fawzi served as president of global research and development at Warner Chilcott, and previously he was part of the senior leadership team at Wyeth before its acquisition by Pfizer.